- About Us
- Investors + Media
- Contact Us
Circadian Technologies Limited is an emerging leader in the field of angiogenesis-based treatments for cancer. Focusing on a class of drug targets called Vascular Endothelial Growth Factors (VEGFs), we seek to develop truly novel therapies to extend and improve the lives of cancer sufferers. Circadians strengths are the following:
Intellectual Property Circadian owns the worlds largest and most comprehensive intellectual property estate covering the key angiogenesis targets VEGF-C, VEGF-D and VEGFR-3. These IP rights include over 50 patent families, 200 granted patents and 500 patents pending worldwide.
Pipeline Circadian has an internal product pipeline comprising biologics-based drugs to three angiogenesis targets. Circadians most advanced program, VGX-100, an antibody-drug targeting VEGF-C, is expected to enter clinical trials in 2011.
Partners Circadian has commercial partnerships with other leading biotechnology companies for the development of products based on the companys technology. Ark Therapeutics is evaluating Trinam in Phase 3 clinical trials. ImClone Systems, a subsidiary of Eli Lilly and Company, is conducting preclinical studies of an anti-VEGFR-3 antibody for cancer treatment.
Management Circadian is run by some of the most experienced and successful people in the Australian biotechnology industry, with an extensive track record of success in product and business development. Members of Circadians leadership team have held past roles with Amgen, Genentech, GlaxoWellcome, Schering and Sanofi-Aventis, among other leading companies.
Financial strength Circadian has a strong financial position and substantial cash reserves.
Circadian Technologies was one of Australias earliest biotechnology companies and was listed on the Australian Stock Exchange in 1985. Originally functioning as a commercial vehicle for outstanding, diverse biomedical research, the company successfully launched and spun out many of Australias most well-known biotechnology companies including Axon Instruments, Optiscan Imaging and Antisense Therapeutics. In 2008 Circadian modified its strategy to focus on the development of biologics-based therapies for cancer, in particular leveraging the product pipeline and broad intellectual property assets of its 100 percent-owned subsidiary, Vegenics Pty Ltd. Vegenics Pty Ltd formally holds the intellectual property rights to develop Vascular Endothelial Growth Factor (VEGF)-based therapies.